CEL-SCI

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2023 financial results and clinical & corporate developments.

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--UK'S National Institute for Health and Care Excellence (NICE) selects Multikine as potential new standard of care for head & neck cancer.

UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $5 million public offering of common stock.

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $5 million offering of common stock.

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI issues letter to shareholders.

CEL-SCI Issues Letter to Shareholders

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals.

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2023--5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, as Presented at Leading Cancer Conference ESMO 2023.

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI readies its Multikine manufacturing facility for commercial scale production.

CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI files request with the UK'S MHRA regarding path to approval for Multikine in the treatment of head & neck cancer.

CEL-SCI Files Request With the UK's MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI submits scientific advice filing To European Medicines Agency (EMA) for Multikine in the treatment of Head & Neck Cancer.

CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2023 financial results.

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of public offering.

CEL-SCI Announces Closing of Public Offering

CEL-SCI (NYSEMKT: CVM ) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering. CEL-SCI is offering up 2.5 million shares of its common stock at a price of $2 per share.

Why Is CEL-SCI (CVM) Stock Down 23% Today?

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of public offering.

CEL-SCI Announces Pricing of Public Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces proposed public offering of common stock.

CEL-SCI Announces Proposed Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI concludes positive meeting with U.S. FDA concerning Multikine's approval for head & neck cancer.

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine's Approval for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #AHNS2023--CEL-SCI reports Phase 3 Tumor PD-L1 Biomarker Data demonstrate Multikine's increased efficacy and potential for combination with checkpoint inhibitors.

CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to present novel data at AHNS 11th International Conference on Head and Neck Cancer—new patent to be filed.

CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESTRO23--Histopathology and tumor biomarker analysis confirm CEL-SCI's Multikine significantly prolonged overall survival in head & neck cancer.

Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation reports second quarter fiscal 2023 financial results.

CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share. The closing of the offering is expected to take place on or about May 2, 2023, subject to the satisfaction of customary closing conditions. In addition, the Company expects to grant the underwrit.

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to pursue Canada's conditional approval pathway for Multikine in the treatment of head & neck cancer.

CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ECHNO--CEL-SCI's Multikine Phase 3 cancer study shows 43% survival extension.

CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ECHNO--CEL-SCI to present new Phase 3 data at European Congress on Head & Neck Oncology.

CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.

News for CEL-SCI Stock (CVM)